3Marcello De Cicco.The prothrombotic state in cancer:pathogenic mechanisms[J].Hematology,2004,50(1):187-196.
4Paolo P,Andrea A,Antonio G.Cancer and venous thromboembolism:An overview[J].Haematologica,1999,84(4):437-445.
5Zangari M,Anaissie E,Barlogie B,et al.Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy[J].Blood,2001,98(5):1614-1615.
6Mary C,Albert W,Richard H,et al.Deep vein thrombosis and pulmonary embolism in two cohorts:the longitudinal investigation of thromboembolism etiology[J].Am J Med,2004,117(7):19-25.
8Bergqvist D,Agnelli G,Cohen AT,et al.Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer[J].N Engl J Med,2002,346(13):975-980.
9Nazario R,Delorenzo LJ,Maguire AG.Treatment of venous thromboembolism[J].Cardiol Rev,2002,10(4):249-259.
1Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta - analysis comparing low - molecular - weight heparins with unfractionated heparin in the treatment of venous tromboembolism: examining some unanswered questions regarding location of treatment, product
2Faivre R, Neuhart Y, Kieffer Y, et al. A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Presse Med,1988, 17: 197-200.
3Yeager BF, Matheny SC. Low - molecular- weight heparin in outpatient treatment of DVT. Am Farm Physician, 1999, 59:945 -952.
4Grole JB. Treatment of deep vein thrombosis using low - molecularweight heparins. Am J Manage Care, 2001, 7 (17 suppl): 515-523.
